Results 211 to 220 of about 59,825 (253)

Human medicines European public assessment report (EPAR): Imatinib Accord, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Dermatofibrosarcoma,Myelodysplastic-Myeloproliferative Diseases,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Hypereosinophilic Syndrome, Date of authorisation: 30/06/2013, Revision: 15, Status: Authorised

Case Medical Research, 2018
Kernel Networks Inc.
openalex   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Human medicines European public assessment report (EPAR): Oncaspar, pegaspargase, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 14/01/2016, Revision: 8, Status: Authorised

Case Medical Research, 2019
openaire   +2 more sources

Early T-cell Precursor Acute Lymphoblastic Leukemia/Lymphoma

Surgical Pathology Clinics, 2013
Discrete diagnostic subtypes of T lymphoblastic leukemia/lymphoma (T-cell acute lymphoblastic leukemia/lymphoma, T-ALL) have historically not been widely recognized. Recently, a novel subset with distinctive immunophenotypic, molecular, and clinical features has been proposed.
David R, Czuchlewski, Kathryn, Foucar
openaire   +2 more sources

Human medicines European public assessment report (EPAR): Oncaspar, pegaspargase, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 14/01/2016, Revision: 7, Status: Authorised

Case Medical Research, 2019
Case Medical Research
openalex   +2 more sources

Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Date of authorisation: 28/06/2017, Revision: 3, Status: Authorised

Case Medical Research, 2018
openaire   +2 more sources

Abstract 3098: Myc preferentially transforms hematopoietic stem cells into Precursor B cell lymphoblastic leukemia/lymphoma

Cancer Research, 2010
Abstract Overexpression of Myc oncogenes (c-Myc, N-Myc and L-Myc) is frequently found in a wide range of tumors. Although many reports have shown that Myc can directly induce tumors in mice models, the cell-of-origin of the Myc-induced tumor is still unclear.
Eiji Sugihara, Takatsune Shimizu, Jo Ishizawa, Seiji Okada, Masanao Miwa, Hideyuki Saya   +5 more
openaire   +1 more source

Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children

Blood, 2019
Survival rates of children with relapsed/refractory (r/r) BCP-ALL remain unsatisfactory and little progress has been made in the past 2 decades. Similarly, relapse of childhood B-NHL is usually associated with an aggressive disease and poor outcomes ...
Francesca Del Bufalo, Concetta Quintarelli, Biagio De Angelis, Ignazio Caruana, Matilde Sinibaldi, Luciana Vinti, Pietro Merli, Mattia Algeri, Annalisa Ruggeri, Federica Galaverna, Valentina Cirillo, Maria Giuseppina Cefalo, Giuseppina Li Pira, Giovanna Leone, Valentina Bertaina, F Fassio, Monica Gunetti, Stefano Iacovelli, Franco Locatelli   +18 more
openalex   +2 more sources

Case Report: B-cell Acute Lymphoblastic Leukemia/Lymphoma Following Castleman Disease

Oncology Treatment Discovery
Castleman disease (CD) is a rare nonmalignant lymphoproliferative disorder presenting systemic symptoms such as fever, night sweats, fatigue, anemia, effusions, and multifocal lymphadenopathy. The etiology of CD has not been clarified to date.
Meng Zhao, Qirui Li, Tao Jiang, Dafei Xu, Qian Ma, Lunfei Tao, Ziwei Miao   +6 more
semanticscholar   +1 more source

Human medicines European public assessment report (EPAR): Imatinib Actavis, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 17/04/2013, Revision: 12, Status: Authorised

Case Medical Research, 2019
Kernel Networks Inc.
openalex   +2 more sources

T and NK lymphoblastic leukemia/lymphoma: Report from the 2023 SH/EAHP Workshop.

American Journal of Clinical Pathology
OBJECTIVES The 2023 Society for Hematopathology/European Association for Hematopathology Workshop addressed advancements in the diagnosis and classification of T- and natural killer (NK)-cell lymphomas/leukemias.
O. Weinberg, C. Bueso-Ramos, R. Kanagal-Shamanna   +2 more
semanticscholar   +1 more source